Central nervous system immune-related disorders after SARS-CoV-2 vaccination : a multicenter study
Copyright © 2024 Vogrig, Tartaglia, Dentoni, Fabris, Bax, Belluzzo, Verriello, Bagatto, Gastaldi, Tocco, Zoccarato, Zuliani, Pilotto, Padovani, Villagrán-García, Davy, Gigli, Honnorat and Valente..
Background: COVID-19 vaccines have been approved due to their excellent safety and efficacy data and their use has also permitted to reduce neurological complications of SARS-CoV-2. However, clinical trials were underpowered to detect rare adverse events. Herein, the aim was to characterize the clinical spectrum and immunological features of central nervous system (CNS) immune-related events following SARS-CoV-2 vaccination.
Methods: Multicenter, retrospective, cohort study (December 1, 2020-April 30, 2022). Inclusion criteria were (1) de novo CNS disorders developing after SARS-CoV-2 vaccination (probable causal relationship as per 2021 Butler criteria) (2); evidence for an immune-mediated etiology, as per (i) 2016 Graus criteria for autoimmune encephalitis (AE); (ii) 2015 Wingerchuk criteria for neuromyelitis optica spectrum disorders; (iii) criteria for myelitis.
Results: Nineteen patients were included from 7 tertiary referral hospitals across Italy and France (one of them being a national referral center for AE), over almost 1 year and half of vaccination campaign. Vaccines administered were mRNA-based (63%) and adenovirus-vectored (37%). The median time between vaccination and symptoms onset was 14 days (range: 2-41 days). CSF was inflammatory in 74%; autoantibodies were detected in 5%. CSF cytokine analysis (n=3) revealed increased CXCL-10 (IP-10), suggesting robust T-cell activation. The patients had AE (58%), myelitis (21%), acute disseminated encephalomyelitis (ADEM) (16%), and brainstem encephalitis (5%). All patients but 2 received immunomodulatory treatment. At last follow-up (median 130 days; range: 32-540), only one patient (5%) had a mRS>2.
Conclusion: CNS adverse events of COVID-19 vaccination appear to be very rare even at reference centers and consist mostly of antibody-negative AE, myelitis, and ADEM developing approximately 2 weeks after vaccination. Most patients improve following immunomodulatory treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 15(2024) vom: 25., Seite 1344184 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vogrig, Alberto [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 21.02.2024 Date Revised 10.04.2024 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2024.1344184 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368655377 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368655377 | ||
| 003 | DE-627 | ||
| 005 | 20240411232338.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240220s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2024.1344184 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1372.xml |
| 035 | |a (DE-627)NLM368655377 | ||
| 035 | |a (NLM)38375477 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vogrig, Alberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Central nervous system immune-related disorders after SARS-CoV-2 vaccination |b a multicenter study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.02.2024 | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Vogrig, Tartaglia, Dentoni, Fabris, Bax, Belluzzo, Verriello, Bagatto, Gastaldi, Tocco, Zoccarato, Zuliani, Pilotto, Padovani, Villagrán-García, Davy, Gigli, Honnorat and Valente. | ||
| 520 | |a Background: COVID-19 vaccines have been approved due to their excellent safety and efficacy data and their use has also permitted to reduce neurological complications of SARS-CoV-2. However, clinical trials were underpowered to detect rare adverse events. Herein, the aim was to characterize the clinical spectrum and immunological features of central nervous system (CNS) immune-related events following SARS-CoV-2 vaccination | ||
| 520 | |a Methods: Multicenter, retrospective, cohort study (December 1, 2020-April 30, 2022). Inclusion criteria were (1) de novo CNS disorders developing after SARS-CoV-2 vaccination (probable causal relationship as per 2021 Butler criteria) (2); evidence for an immune-mediated etiology, as per (i) 2016 Graus criteria for autoimmune encephalitis (AE); (ii) 2015 Wingerchuk criteria for neuromyelitis optica spectrum disorders; (iii) criteria for myelitis | ||
| 520 | |a Results: Nineteen patients were included from 7 tertiary referral hospitals across Italy and France (one of them being a national referral center for AE), over almost 1 year and half of vaccination campaign. Vaccines administered were mRNA-based (63%) and adenovirus-vectored (37%). The median time between vaccination and symptoms onset was 14 days (range: 2-41 days). CSF was inflammatory in 74%; autoantibodies were detected in 5%. CSF cytokine analysis (n=3) revealed increased CXCL-10 (IP-10), suggesting robust T-cell activation. The patients had AE (58%), myelitis (21%), acute disseminated encephalomyelitis (ADEM) (16%), and brainstem encephalitis (5%). All patients but 2 received immunomodulatory treatment. At last follow-up (median 130 days; range: 32-540), only one patient (5%) had a mRS>2 | ||
| 520 | |a Conclusion: CNS adverse events of COVID-19 vaccination appear to be very rare even at reference centers and consist mostly of antibody-negative AE, myelitis, and ADEM developing approximately 2 weeks after vaccination. Most patients improve following immunomodulatory treatment | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a neurologic adverse events | |
| 650 | 4 | |a neurological complications | |
| 650 | 4 | |a vaccination | |
| 650 | 4 | |a vaccine | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Tartaglia, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Dentoni, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Fabris, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Bax, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Belluzzo, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Verriello, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Bagatto, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Gastaldi, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Tocco, Pierluigi |e verfasserin |4 aut | |
| 700 | 1 | |a Zoccarato, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Zuliani, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Pilotto, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Padovani, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Villagrán-García, Macarena |e verfasserin |4 aut | |
| 700 | 1 | |a Davy, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Gigli, Gian Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Honnorat, Jérôme |e verfasserin |4 aut | |
| 700 | 1 | |a Valente, Mariarosaria |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 15(2024) vom: 25., Seite 1344184 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g day:25 |g pages:1344184 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2024.1344184 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |b 25 |h 1344184 | ||